Cambrex expands US API capacity
Small molecule CDMO Cambrex is spending $50 million to expand its mid- and large-scale API manufacturing capacity in Charles City, Iowa. This is the sixth major investment at the site in the past eight years and follows on from a recent, smaller expansion at the site in Karlskroga, Sweden.
The investment was driven by continued strong demand for outsoured small molecule manufacture. It will be operational in early 2022, will add three large-scale and one mid-scale manufacturing work centres, increasing the site’s capacity by 30%. When this is completed, the site will employ more than 400 people.
Earlier this year, Cambrex spent $3.6 million to increase flexible drug substance manufacturing capacity by 6 m? (25%) at Karlskoga. This work is now nearing completion. It includes converting a previously customer-dedicated manufacturing train for general use, modifying a four-reactor configuration and installing new holding tanks, plus a 4 m2 Hastelloy Rosemund filter.